Mesenchymal Stem Cell Therapy and Alzheimer’s Disease: Current Status and Future Perspectives
The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common progressive neurodegenerative disease worldwide, but its cause remains unclear. Although a few drugs can provide temporary and partial relief of symptoms in some patients, no curative treatment is available. Therefore, attention has been focused on research using stem cells to treat AD. Among stem cells, mesenchymal stem cells (MSCs) have been used to treat the related pathologies in animal models of AD, and other neurodegenerative disease. This review describes latest research trends on the use of MSC-based therapies in AD and its action of mechanism. MSCs have several beneficial effects. They would be specified as the reduction of neuroinflammation, the elimination of amyloid-β, neurofibrillary tangles, and abnormal protein degradation, the promotion of autophagy-associated and blood-brain barrier recoveries, the upregulation of acetylcholine levels, improved cognition, and the recovery of mitochondrial transport. Therefore, this review describes the latest research trends in MSC-based therapy for AD by demonstrating the importance of MSC-based therapy and understanding of its mechanisms in AD and discusses the limitations and perspectives of stem cell therapy in AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
1 retracted
Salem, A. M., Ahmed, H. H., Atta, H. M., Ghazy, M. A., & Aglan, H. A. (2014) · Cell Biology International · doi:10.1002/cbin.10331 · Cited by 56 · cited 1×
“In an AD rat model with hippocampal A (cid:2) lesions, a single intravenous injection of BM-MSCs resulted in the complete elimination of A (cid:2) [38].”
RetractedTakahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
Autophagy: Renovation of Cells and Tissues
Mizushima, N., & Komatsu, M. (2011) · Cell · doi:10.1016/j.cell.2011.10.026 · Cited by 6,418 · cited 1×
“Under normal conditions, autophagy plays an important role in maintaining cellular homeostasis by breaking down unnecessary or abnormal cellular components; however, dysfunctions in autophagy are associated with cancer, inflammatory, and neurodegenerative diseases [43, 44].”
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511 · cited 1×
“Fourth, MSCs are rarely immunogenic as they do not express MHC class II or co-stimulatory molecules (CD80, CD86, or CD40) [17], as well as suppress the activations and proliferations of T and B lymphocytes [18–20], and the differentiations and maturations of dendritic cells [21, 22].”
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076 · cited 2×
“BBB breakdown leads to accumulation of neurotoxic materials and the activations of astrocytes and microglia and inflammatory response [49], leading to accumulation of the fibrous scraps of cells such as pericyte and endothelial cells, which make drug absorption or therapeutic delivery to the brain…”
Rubinsztein, D. C., Mariño, G., & Kroemer, G. (2011) · Cell · doi:10.1016/j.cell.2011.07.030 · Cited by 2,107 · cited 1×
“Under normal conditions, autophagy plays an important role in maintaining cellular homeostasis by breaking down unnecessary or abnormal cellular components; however, dysfunctions in autophagy are associated with cancer, inflammatory, and neurodegenerative diseases [43, 44].”
Immunomodulatory properties of mesenchymal stromal cells
Nauta, A. J., & Fibbe, W. E. (2007) · Blood · doi:10.1182/blood-2007-02-069716 · Cited by 1,788
Human mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
Research works printed but not linked: 1
- Alzheimer’s Disease International, 2019, World Alzheimer Report 2019. Attitudes to dementia.
Cited by
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
“Nonetheless, a small number of preclinical investigations have demonstrated advancements in the modelling of AD pathology utilizing ESCs (Kim et al., 2020a).”
BackgroundInfluentialSafiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
Sha, S., Shen, X., Cao, Y., & Qu, L. (2021) · Aging · doi:10.18632/aging.203088 · Cited by 107
New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease
Zhang, F., Zhong, R.-J., Cheng, C., Li, S., & Le, W.-D. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00565-5 · Cited by 105
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
“Second, they are less prone to transformation into neoplastic cells [169].”
BackgroundMesenchymal Stem Cell Therapy for Alzheimer’s Disease
Hernández, A. E., & García, E. (2021) · Stem Cells International · doi:10.1155/2021/7834421 · Cited by 84
“In addition, MSCs also possess a low risk of differentiating into cancer cells and are infrequently immunogenic [23].”
BackgroundReconsidering the role of blood-brain barrier in Alzheimer’s disease: From delivery to target
Sousa, J. A., Bernardes, C., Bernardo-Castro, S., Lino, M. M., Albino, I., Ferreira, L., Brás, J., Guerreiro, R. J., Tábuas‐Pereira, M., Baldeiras, I., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1102809 · Cited by 71
The blood-brain barrier, a key bridge to treat neurodegenerative diseases
Hang, Z., Zhou, L., Xing, C., Wen, Y., & Du, H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102070 · Cited by 48
Ma, S., Zhou, X., Wang, Y., Li, Z., Wang, Y., Shi, J., & Guan, F. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102325 · Cited by 45
Transplantation of Nasal Olfactory Mucosa Mesenchymal Stem Cells Benefits Alzheimer’s Disease
Hong, C., Chen, M., Duan, R., Wang, X., Pang, Z., Ge, L., Lü, M., Xie, H., & Liu, Z. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03044-6 · Cited by 45
“1 3 beneficial effects in AD, including the reduction of neuroinflammation, tangle elimination and promotion of autophagy, and improved cognition [36].”
BackgroundAlzheimer’s Disease: From Pathogenesis to Mesenchymal Stem Cell Therapy – Bridging the Missing Link
Hu, J., & Wang, X. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.811852 · Cited by 49
Stem Cell Therapy for Alzheimer’s Disease: A Scoping Review for 2017–2022
Duan, Y., Lyu, L., & Zhan, S. (2023) · Biomedicines · doi:10.3390/biomedicines11010120 · Cited by 41
“Stem cell therapy can also eliminate neurofibrillary tangles and abnormal degradation of proteins, and promote mitochondrial transport to improve cognition [18].”
BackgroundInfluentialSkok, M. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i8.1072 · Cited by 38
Iron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer’s Disease Treatment
Jung, M., Kim, H., Hwang, J. W., Choi, Y., Kang, M., Kim, C., Hong, J., Lee, N. K., Moon, S., Chang, J. W., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c03682 · Cited by 34
Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
Zhang, Y., Chen, J., Li, Y., Jiao, B., & Luo, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102595 · Cited by 38
Recent Insights into the Neurobiology of Alzheimer’s Disease and Advanced Treatment Strategies
Anitha, K., Singh, M. K., Kohat, K., Varshini, T. S., Chenchula, S., Padmavathi, R., Amerneni, L. S., Vishnu Vardhan, K., Mythili Bai, K., Chavan, M. R., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04384-1 · Cited by 42
“A rapidly developing discipline called stem cell therapy has the potential to treat neurodegenerative diseases such as AD, among other medical conditions [99].”
Hernando, S., Santos‐Vizcaíno, E., Igartúa, M., & Hernández, R. M. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1898 · Cited by 37
Chen, X., Jiang, S., Wang, R., Bao, X., & Li, Y. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220721 · Cited by 39
Stem Cell-based Therapeutic and Diagnostic Approaches in Alzheimer's Disease
Abdi, S., Javanmehr, N., Ghasemi-Kasman, M., Bali, H. Y., & Pirzadeh, M. (2021) · Current Neuropharmacology · doi:10.2174/1570159x20666211231090659 · Cited by 33
“Besides that, MSCs express no or low major histocompatibility complex II (MHC II) or costimulatory molecules [95]; suppressing T and B cells is another function of MSCs, therefore, allogeneic MSCs can be a therapeutic tool free of immune rejection concerns [96].”
Correlation Between Exosomes and Neuro-inflammation in Various Brain Disorders
Kumar, P., Sharma, H., Singh, A., Pandey, S. N., & Chandra, P. (2024) · Springer eBooks · doi:10.1007/978-981-99-8373-5_11 · Cited by 35
Comprehensive Bibliometric Analysis of Stem Cell Research in Alzheimer’s Disease from 2004 to 2022
Wang, R., Zhu, Y., Qin, L.-F., Xu, Z., Gao, X.-R., Liu, C., Xu, G., & Chen, Y. (2023) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000528886 · Cited by 25
A consolidated review on stem cell therapy for treatment and management of Alzheimer's disease
Ahmad, F., & Sachdeva, P. (2022) · Aging Medicine · doi:10.1002/agm2.12216 · Cited by 26
Joshi, R., Missong, H., Mishra, J., Kaur, S., Saini, S., Kandimalla, R. J. L., Reddy, P. H., Babu, A. M., Bhatti, G. K., & Bhatti, J. S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105067 · Cited by 25
Lai, Y.-F., Lin, T.-Y., Ho, P.-K., Chen, Y., Huang, Y.-C., & Lu, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137143 · Cited by 22
Mo, H., Kim, J., Kim, J. Y., Kim, J. W., Han, H., Choi, S. H., Rim, Y. A., & Ju, J. H. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00384-8 · Cited by 22
“In addition, studies using existing MSCs have demonstrated an improved anti-amyloid environment, but the limitation of insufficient potency persists [28, 29].”
BackgroundSelf-citationCandelise, N., Santilli, F., Fabrizi, J., Caissutti, D., Spinello, Z., Moliterni, C., Lancia, L., Monache, S. D., Mattei, V., & Misasi, R. (2023) · Cells · doi:10.3390/cells12131686 · Cited by 23
Bhatt, A., Bhardwaj, H., & Srivastava, P. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.07.019 · Cited by 23
Tolédano, A., Rodríguez‐Casado, A., Álvarez, M., & Toledano‐Díaz, A. (2024) · Brain Sciences · doi:10.3390/brainsci14111101 · Cited by 21
Lee, M., Lim, H., Kim, M., Park, G.-S., Nam, K., Lee, Y. H., & Kim, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-86306-y · Cited by 20
Self-citationHoveizi, E., Naddaf, H., Ahmadianfar, S., & Gutmann, J. L. (2023) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2022.12.009 · Cited by 18
Stem cells in the treatment of Alzheimer's disease – Promises and pitfalls
Bhatti, J. S., Khullar, N., Mishra, J., Kaur, S., Sehrawat, A., Sharma, E., Bhatti, G. K., Selman, A., & Reddy, P. H. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166712 · Cited by 22
Proposed Mechanisms of Cell Therapy for Alzheimer’s Disease
Belousova, E., Salikhova, D. I., Maksimov, Y., Nebogatikov, V. O., Sudina, A. K., Goldshtein, D. V., & Ustyugov, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212378 · Cited by 19
“However, preclinical research on ESCs in animal models is ongoing [43].”
Kim, I.-K., Park, J., Kim, B., Hwang, K., & Song, B. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i9.1215 · Cited by 21
Jeyaraman, M., Rajendran, R. L., Muthu, S., Jeyaraman, N., Sharma, S., Jha, S. K., Muthukanagaraj, P., Hong, C. M., da Fonseca, L. F., Lana, J. F., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17808 · Cited by 17
Bruno, A., Milillo, C., Anaclerio, F., Buccolini, C., Dell’Elice, A., Angilletta, I., Gatta, M., Ballerini, P., & Antonucci, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020976 · Cited by 18
“Shortly, this may occur through the development of new stem cell-based technologies (including the use of engineered stem cells, biological scaffolds, and other new materials [102], such as nano-sized microvesicles), which will drastically change this field.”
BackgroundLiu, J., Hou, Z., Wu, J., Liu, K., Li, D., Gao, T., Liu, W., An, B., Sun, Y., Mo, F., et al. (2021) · Cell Proliferation · doi:10.1111/cpr.13085 · Cited by 18
Wang, Z., Li, H., Fang, J., Wang, X., Dai, S., Cao, W., Guo, Y., Li, Z., & Zhu, H. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10320-w · Cited by 14
Yin, B., Li, X., Li, Z., Zhu, X., Zhang, L., Zhou, X., Xu, J., Chen, F., Tang, P., & Gao, F. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202306326 · Cited by 13
Zhang, K., Du, X., Gao, Y., Liu, S., & Xu, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221253 · Cited by 13
“Neurofibrillary tangles are formed by the hyperphosphorylation of tau, and the intracellular abundance of tau is negatively correlated with lifespan in patients with AD [4].”
Sharma, H. S., Muresanu, D. F., Nozari, A., Lafuente, J. V., Buzoianu, A. D., Sahib, S., Tian, Z. R., Bryukhovetskiy, I., Manzhulo, I., Menon, P. K., et al. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.04.008 · Cited by 12
Tolstova, T. V., Dotsenko, E., Luzgina, N. G., & Rusanov, A. L. (2024) · Biomedicines · doi:10.3390/biomedicines12102243 · Cited by 12
“These effects are primarily associated with the influence of MSCs on neuroinflammation and microglia [3].”
BackgroundYao, X., Wang, W., Li, Y., Cao, Z., Wang, Y., Yuan, Y., Li, X., Liang, X., Yu, Y., & Liu, L. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136825 · Cited by 10
Roles of Microglia in AD Pathology
Gao, R., Wu, H., Li, Q., & Zhao, J. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230203112351 · Cited by 10
Yi, H., Wu, S., Wang, X., Liu, L., Wang, W., Yu, Y., Li, Z., Jin, Y., Liu, J., Zheng, T., et al. (2024) · BMC Neuroscience · doi:10.1186/s12868-024-00849-0 · Cited by 10
Mobasheri, K., Zaefizadeh, M., Ghobeh, M., & Eidi, A. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221095 · Cited by 9
“Despite its many medicinal properties, quercetin has low bioavailability on account of its poor sol-ubility in water and rapid metabolism, and its lack of targeted transfer limits its use [2–5].”
Current state of stem cell research in non-human primates: an overview
Wu, J., Shi, Y., Yang, S., Tang, Z., Li, Z., Li, Z., Zuo, J., Ji, W., & Niu, Y. (2023) · Medical Review · doi:10.1515/mr-2023-0035 · Cited by 11
“If AD progresses to a state of hyperphosphorylation of Tau protein and cognitive impairment, therapeutic strategies using MSCs should be considered [46].”
BackgroundWu, J., Chen, J., Ge, Y., Huang, N., & Luo, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29424 · Cited by 11
“In addition, BMSC have a low risk of differentiating into cancer cells and are rarely immunogenic [34].”
BackgroundWu, J., Geng, C., Liu, L., & Tang, Y. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100112 · Cited by 9
Zhang, R., Li, C., Du, R., Yuan, Y., Zhao, B., Zhang, Y., & Wang, C. (2021) · Biocell · doi:10.32604/biocell.2022.017248 · Cited by 7
Stem cell-based therapeutic strategies for down syndrome and Alzheimer’s disease
Hamadelseed, O., & Skutella, T. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04556-3 · Cited by 6
“This study further suggested that protein-iPSCs could improve cognition in AD by reducing amyloid plaques and promoting oligodendrocyte-derived neuronal support [44].”
Karsuntseva, E. K., Voronova, A. D., Andretsova, S. S., Shishkina, V. S., Chadin, A. V., Fursa, G. A., Fedorov, A. V., Reshetov, I. V., Stepanova, O. V., & Chekhonin, V. P. (2024) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-024-06293-8 · Cited by 5
“However, the high tumorigenicity of ESCs and iPSCs [16], low survival rate of MSCs [17] and NSPCs [18], and some bioethical and technological dif - ficulties associated with finding the donor and source of cells [19] limit their clinical use in AD therapy.”
Sharma, H. S., Muresanu, D. F., Nozari, A., Lafuente, J. V., Buzoianu, A. D., Tian, Z. R., Huang, H., Feng, L., Bryukhovetskiy, I., Manzhulo, I., et al. (2023) · Advances in neurobiology · doi:10.1007/978-3-031-32997-5_4 · Cited by 5
Ma, C., Zhu, H., Cai, Y., Li, N., Han, Z., Wu, H., & Chen, H. (2025) · Journal of Biophotonics · doi:10.1002/jbio.202400468 · Cited by 4
The involvement of HIF-1α–dependent paracrine factors in Alzheimer’s disease
Zhdankina, V. I., Perepelitsa, E. S., Blagova, A. V., Komleva, Y. K., Baranich, T. I., & Salmina, A. B. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2025-0102 · Cited by 4
“MSCs have demonstrated multiple therapeutic e ff ects against AD, including reductions in amyloid accumulation, tau phosphorylation, mitochondrial stress, and proin-fl ammatory responses and enhancements in functional vascularity and neurobehavioral performance (Kim et al. 2020).”
Yang, H., You, X., Yue, C., Yu, X., Yue, X., Zheng, X., Yan, X., Li, J., Bi, J., Zhang, L., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251390553 · Cited by 3
“43,44 For instance, et al. veri fi ed the immunomodulatory and neuroprotective effect of intra-nasal delivery of MSC-exo upon a 3 × Tg model of AD.”
Pezeshki, S. P., Darabi, M. K., Nazeri, Z., Sarkaki, A., Rashidi, M., Babaahmadi‐Rezaei, H., Kheirollah, A., & Cheraghzadeh, M. (2023) · PubMed Central · doi:10.22088/ijmcm.bums.12.2.108 · Cited by 3
Kim, H., Lee, S., Chang, J. W., Kim, A. R., Jang, H., & Na, D. L. (2021) · Journal of Visualized Experiments · doi:10.3791/62120 · Cited by 2
Self-citationTENG, H., Cho, M., MA, Z., Ji, X., Jin, S., ZHOU, Y., Xuan, M., Seong, H., LI, X., CHOI, S.-H., et al. (2024) · In Vivo · doi:10.21873/invivo.13825 · Cited by 1
“Consequently, current research endeavors are focused on developing new strategies based on previous findings aimed at enhancing the safety and efficacy of stem cells (7-9).”
Begh, M. Z. A., Zehravi, M., Bhuiyan, M. A. K., Molla, M. R., Raman, K., Emran, T. B., Ullah, H., Ahmad, I. S., Osman, H., & Khandaker, M. U. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156013 · Cited by 1
Borkowska, P., Morys, J., Zielińska, A., & Kowalski, J. (2023) · Biomedicines · doi:10.3390/biomedicines11061751 · Cited by 2
Stem cell-based therapy for Alzheimer’s disease
Belousova, E. V., Salikhova, D. I., Nebogatikov, V. O., Ustyugov, A. A., & Goldshtein, D. V. (2024) · Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science) · doi:10.57034/2618723x-2024-01-06 · Cited by 1
PBM Combined with hUCMSCs Modulates the Polarization of MicrogliaPreprint
Chen, H., Zhu, H., Cai, Y., Guo, J., Liu, P., Han, Z., Wei, X., & Liu, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4096663/v1 · Cited by 1
Yin, B., Li, X., Li, Z., Zhu, X., Zhang, L., Zhou, X., Xu, J., Chen, F., Tang, P., & Gao, F. (2023) · Angewandte Chemie · doi:10.1002/ange.202306326
Beclin-1 Improves the Cognitive Function of Mice with Alzheimer’s Disease
Li, S. H. A. O., He, Q. W., Xin, D. U., Li, Q., Yang, S., Chen, D. O. N. G., & Pengju, M. A. (2023) · Kafkas Universitesi Veteriner Fakultesi Dergisi · doi:10.9775/kvfd.2023.30057
“Despite growing evidence that stem cell therapy is a promising strategy for treating AD, the chronic pathological microenvironment in the brain is not conducive to the survival of transplanted stem cells [28] .”
Initiating and Facilitating Brain Repair: Factors, Principles, and Mechanisms
Zamproni, L. N., & Porcionatto, M. A. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-49744-5_1
Analysis of genes associated with Alzheimer's disease and endoplasmic reticulum stressPreprint
Liu, Z., & Li, F. (2024) · Research Square · doi:10.21203/rs.3.rs-4334229/v1
Li, N., Zhu, H., Cai, Y., Guo, J., Liu, P., Han, Z., Wu, H., Liu, Y. F., & Chen, H. (2024) · Research Square · doi:10.21203/rs.3.rs-4697618/v1
Stem cell therapy as a novel concept to combat CNS disorders
Kumar, R., Mahajan, S., Gupta, U., Madan, J., Godugu, C., Guru, S. K., Singh, P. K., Parvatikar, P., & Maji, I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23841-3.00009-1
Effects of Dexamethasone and Tacrolimus on Mesenchymal Stem Cell Characteristics and Gene Expression
Lee, N. K., Na, D. L., Myeong, S. H., Lee, S.-Y., Lee, N.-H., Jang, H., Seo, S. W., Chang, J. W., Kim, H. J., & Son, H. J. (2025) · International Journal of Stem Cells · doi:10.15283/ijsc24116
“Mesenchymal stem cells (MSCs) are frequently used in both preclinical and clinical settings because of their advantageous properties, including high accessibility, yield, paracrine activity, and hypo-immunogenicity (1, 2).”
Self-citationFuture of adult stem cells in regenerative medicine
Asgharzadeh, F., Yaghoubi, A., Nazarnezhad, S., Saeinasab, M., & Sefat, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34152-6.00016-0
Mo, H., Kim, J., Kim, J. Y., Kim, J. W., Han, H., Choi, S. H., Rim, Y. A., & Ju, J. H. (2023) · Figshare · doi:10.6084/m9.figshare.24540589
Self-citationThe impact of NGF overexpression on proteome profile in WJ-MSC cultures
Borkowska, P., Krawczyk, A., Kowalczyk, M., Zielińska, A., Kuśmierz, D., Rother, M. B., & Paul-Samojedny, M. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150139
Dhapola, R., Kumari, S., Sharma, P., Paidlewar, M., Vellingiri, B., Cho, S.-G., Dayem, A. A., Medhi, B., & HariKrishnaReddy, D. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02418-9
Lu, W., Yan, J., & Feng, H. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71211
Metadata
- Authors
- Kim, J., Lee, Y., Lee, S., Kim, K., Song, M., & Lee, J.
- Affiliations
- Department of Pharmacy, College of Pharmacy, Pusan National University, Busan, Republic of Korea
- Korea Brain Research Institute (KR)
- Pusan National University (KR)
- University of Cambridge (GB)
- Corresponding author
- Song, Minjung
- Lee, Jaewon
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2020-09-01
- Volume
- 77
- Issue
- 1
- Pages
- 1-14
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W3046677722
- Cited by
- 73
- References
- 96
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 20 · 2023: 24 · 2022: 8 · 2021: 9 · 2020: 1
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- mesenchymal stem cells, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Forecasting, Humans, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Neurofibrillary Tangles, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.